Ellen de Brabander - 01 Mar 2024 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Role: Executive Vice President of Innovation and Regulatory Affairs
Signature: /s/ Amy C. Seidel, as Attorney-in-Fact for Ellen de Brabander
Issuer symbol: ELAN
Transactions as of: 01 Mar 2024
Net transactions value: -$156,677
Form type: 4
Filing time: 05 Mar 2024, 16:25:44 UTC
Previous filing: 01 Mar 2024
Next filing: 02 Apr 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ELAN	Common Stock	Award	$0	+31,847	+34%	$0.000000	124,660	01 Mar 2024	Direct	F1
transaction	ELAN	Common Stock	Tax liability	$156,677	-9,774	-7.8%	$16.03	114,886	01 Mar 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELAN	Employee Stock Option(right to buy)	Award	$0	+69,456		$0.000000	69,456	01 Mar 2024	Common Stock	69,456	$16.03	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant of restricted stock units pursuant to the Amended and Restated 2018 Elanco Stock Plan on March 1, 2024, one-third vesting on March 1, 2025, one-third vesting on March 1, 2026, and the remaining vesting on March 1, 2027.
F2	Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the Amended and Restated 2018 Elanco Stock Plan.
F3	Grant of stock options vesting as follows: one-third vesting on March 1, 2025, one-third vesting on March 1, 2026, and the remaining vesting on March 1, 2027.

Remarks:

Executive Vice President of Innovation and Regulatory Affairs